- Home
- » Tags
- » Necitumumab
Top View
- Progress in EGFR-Mutant NSCLC
- Injectable Anti-Cancer Medications
- Novel Third-Generation EGFR Tyrosine Kinase Inhibitors And
- Lilly Presenta En ASCO Nuevos Resultados De Su Portfolio Y Su Pipeline En Oncología
- Partnerre Trigger Pharmaceuticals (At 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J0800 Acthar®
- (INN) for Biological and Biotechnological Substances
- FDA Briefing Document Oncologic Drugs Advisory Committee Meeting
- Treatment of Advanced Squamous Cell Carcinoma of the Lung: a Review
- Bladder Cancer
- Clinical Potential of Necitumumab in Non-Small Cell Lung Carcinoma
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Combination Therapy for EGFR-Mutant Lung Cancers
- Non-Small Cell Lung Cancer
- First-Line Treatment of Patients with Advanced Or Metastatic Squamous Non-Small Cell Lung Cancer: Systematic Review and Network Meta-Analysis
- Spotlight on Necitumumab in the Treatment of Non-Small-Cell Lung Carcinoma
- 2SPD-032 Network Meta-Analysis of Therapeutic Alternatives in Untreated
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- EGFR Positive (EGFR+) Lung Cancer? ABOUT LUNG BIOMARKERS
- Assessment Report
- Partnerre Trigger Pharmaceuticals (At 5.21.21) Code Brand Name Generic Name Code Brand Name Generic Name J3590 Abecma®
- Portrazza, INN-Necitumumab
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
- Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Meet AZN Management: ASCO 2019
- Copyrighted Material
- (M) of SARS-Cov-2
- Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance Atrish Bagchi1,2, Jaafar N
- Oncology Medications Policy (1403)
- (12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
- Cross Discipline Team Leader Review
- Emetogenic Potential of Antineoplastic Agents
- Lilly Highlights Advancements in Its Oncology Portfolio with New Data at ESMO 2016
- Monoclonal Antibodies in Non-Small-Cell Lung Cancer
- Targeted Therapy for NSCLC–A Double-Edged Sword?
- Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in T790M-Positive Non-Small Cell Lung Cancer: Review on Emerged Mechanisms of Resistance
- Oncology Therapy for the Generalist
- Risk-Management-Plan Summary
- Metastatic Squamous Non-Small Cell Lung Cancer (Sqnsclc)
- Drug Prior Authorization Requirements (Office, Home Or Outpatient Setting) Effective January 1, 2021*
- Oncology Drugs in the Pipeline
- Highlights of the Nccn Oncology Research Program
- Efficacy of Sym004 in Patients with Metastatic Colorectal Cancer With
- Molecular Basis for Necitumumab Inhibition of EGFR Variants
- Lilly and Merck Expand Immuno-Oncology Collaboration
- 2SPD-034 Use of Daratumumab Based Treatments in Patients With
- Transforming Into Oncology- Sunao Manabe President and COO June 2, 2019 ASCO Investor Relations Presentation, Chicago, IL Forward-Looking Statements
- Portrazza™ (Necitumumab)
- Immuno-Oncology Management Best Practices 2.0
- Ramucirumab LY3009806 IMC-1121B
- EGFR Exon 20 Insertions in Advanced Non-Small Cell Lung Cancer a New
- PORTRAZZA (Necitumumab) Injection, for Intravenous Use and After PORTRAZZA
- Prior Authorization — Premium
- Crizanlizumab-Tmca
- Clinical Trials Appendix Q1 2021 Results Update
- Biological Product Deviation Reporting and HCT/P Deviation Reporting – Non-Blood Product Codes
- (INN) for Biological and Biotechnological Substances
- Paclitaxel-Carboplatin-Pembrolizumab Combination (PC Pembrolizumab) Has Been Recently Authorised in This Indication
- 125547Orig1s000
- Necitumumab (Portrazza)
- Algorithm for the Treatment of Advanced Or Metastatic Squamous Non-Small-Cell Lung Cancer: an Evidence-Based Overview
- A Retrospective Examination of the Us Food and Drug Administration's Clinical Pharmacology Reviews of Oncology Biologics for P
- Necitumumab Portrazza
- Monoclonal Antibodies in Cancer Therapy
- Recommended INN: List 62
- Crizanlizumab-Tmca
- Shaping the Current and Future Treatment of NSCLC with ALK and ROS1 Rearrangements
- Assessment of the Evolution of Cancer Treatment Therapies
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Necitumumab (Portrazza) Reference Number: ERX.SPA.282 Effective Date: 12.01.18 Last Review Date: 11.20 Line of Business: Commercial, Medicaid Revision Log
- Updated Insights on EGFR Signaling Pathways in Glioma
- Necitumumab (Portrazza®)